Medco Beats Targets

"Medco closed 2005, our second full year as an independent company, significantly advancing each of our strategic objectives: Winning and retaining business to achieve strong net-new growth; forming the nation's largest specialty care pharmacy by virtue of our acquisition of Accredo; accelerating the acceptance and use of generic medicines; and launching a nationwide Medicare-approved Part D benefit with a broad suite of products and services to support the needs of our clients and provide millions of seniors access to affordable coverage," said CEO David B. Snow Jr. "In addition to surpassing its financial targets for 2005, Medco closed the year with more than $3 billion in annualized new business. This new sales momentum continues into 2006, with $2.7 billion in new annualized business wins to date -- placing the company in a net-new sales position of $700 million, to date."

The company said it expects to make $2.57 to $2.64 a share for 2006, excluding amortization costs. That's in line with the $2.61 Thomson estimate.

>To order reprints of this article, click here: Reprints